Medsafe, TGA, ASA/AANA, MHRA, Health Canada, GCC — what Nouri can say legally, and where.
Core finding: In every jurisdiction Nouri operates in or targets — New Zealand, Australia, UK, Canada, and GCC — marketing copy is a regulatory instrument. The same product with different wording can be either freely sold as a dietary supplement or reclassified as a medicine requiring full pharmaceutical approval. In Australia alone, this enforcement posture produced 70+ infringement notices totalling AU$1 million against 19 entities in just eight months (January–August 2024), with maximum corporate penalties reaching AU$15.65 million per breach.[15]
The marketing-transforms-classification principle is not a soft guideline — it is the stated operating doctrine of every regulator in Nouri's footprint. Medsafe (NZ) holds that any claim that "implies, alludes, suggests or refers to a therapeutic purpose" converts a supplement into a medicine under Section 4 of the Medicines Act 1981.[16] The TGA (AU) frames it more starkly: "a change in wording on a label can alter the entire regulatory pathway."[4] The MHRA (UK) applies a tie-break rule — a product that qualifies as both food and medicinal product is classified as the medicinal product.[8] This convergence across five distinct legal systems means Nouri's marketing review process is not a compliance formality; it is the primary gate determining which regulatory regime each product enters.
GLP-1 adjacency is the highest-velocity enforcement category in 2024–2025, and the scope of the prohibition extends well beyond naming Ozempic or Wegovy. In August 2025, the UK ASA issued 5 rulings against supplement brands making GLP-1-adjacent claims — banning phrases including "like GLP-1 drugs just natural," "boosts GLP-1-production," "support metabolism," and "reduce blood sugar spikes."[19] The product name "Faux-Zempic" was itself ruled a prohibited drug-equivalence implication. Critically, the UK ASA deployed an AI Active Ad Monitoring system in 2025 that proactively scans for GLP-1-adjacent claims without waiting for consumer complaints — a materially different enforcement posture than the reactive models in NZ and AU.[19] Australia's TGA separately requested the removal of 3,000+ online ads for weight-loss therapeutic goods in 2024–25, and banned compounded GLP-1 products from all pharmacy compounding exemptions from 1 October 2024.[15]
Australia's ARTG listed medicine pathway (AUST L) is the mandatory pre-market step for any supplement sold in-market, but its apparent accessibility — sponsor self-certification, no TGA efficacy review — is offset by a tightly constrained claims universe. As of 2024, approximately 778 permissible indications are available for listed medicines.[21] Each indication contains a fixed therapeutic action and target; paraphrases and synonyms are explicitly prohibited, and Table 6 of the TGA Evidence Guidelines lists controlled substitutions for weight-loss-related terms. Sponsors must hold supporting evidence at the time of ARTG listing — before any advertising commences. The TGA's compliance posture combines post-market surveillance with active monitoring: unlawful supply and advertising of unapproved weight-loss medicines is a stated TGA compliance priority for 2023–25, and the financial exposure is asymmetric — Midnight Health Pty Ltd collected AU$198,000 in infringement notices in 2024.[5]
New Zealand currently requires no pre-market registration for dietary supplements, but the regulatory environment is in active flux. Government policy on the future of natural health products was agreed 25 September 2024, with a Sapere Research Group comparison of NHP frameworks across six jurisdictions commissioned as the basis for reform.[18] Two widely-used marketing terms — "complementary health care product" and "natural health product" — are not legally defined in any New Zealand statute, meaning they provide zero regulatory protection; products using them still face the full supplement-versus-medicine boundary test.[16] NZ's sole channel advantage is unusual: it is one of two countries globally (alongside the USA) where direct-to-consumer advertising of prescription medicines is legal — but this DTC exception applies to medicines only, not to supplements claiming therapeutic effects.[18]
Canada is the most structurally demanding market on Nouri's expansion path. Unlike NZ, AU, and UK — which all operate post-market compliance models — sale of any natural health product in Canada requires a Natural Product Number (NPN) product licence before market entry.[9] Health Canada's NNHPD has issued approximately 90,000 product licences since 2004, demonstrating pathway viability, but the review timeline against Health Canada's 180-day target means Canadian market entry requires a 12–18 month lead time on the application. The market context makes this worth pursuing: approximately 3 million Canadian adults are currently taking GLP-1 drugs, with generic semaglutide approval (Canada was the first G7 nation) expected to reduce access costs by up to 65% — creating significant adjacent supplement demand.[9]
The Gulf GCC markets present two hard prerequisites unrelated to claims language. First, halal certification is mandatory for any product containing animal-derived ingredients — gelatin capsules being the most common trigger — and must be obtained before SFDA or MOHAP registration is initiated.[10] Second, UAE labelling must be bilingual (English and Arabic) as a market entry condition.[10] Saudi Arabia's SFDA is assessed as the strictest regulatory body in the GCC, requiring full product registration against technical standard SFDA.FD 55 before market entry, with updated guidance issued in Q1 and Q2 2024. The UAE routes split by claims type: food supplement claims route through the Dubai Municipality Montaji portal; any metabolic or therapeutic claims require classification and registration through MOHAP — a significantly higher bar.[10]
The UK's post-Brexit framework adds a criminal dimension absent from the other markets. Using an unauthorized nutrition or health claim — one not listed on the GB or NI Health Claims Register — is a criminal offence under the Nutrition and Health Claims (England) (Amendment) Regulations 2024, in force since 1 October 2024.[8] The only pre-approved pathway for high-level health claims is Schedule 4's 13 pre-approved relationships — self-substantiation is not permitted for this tier.[14] While no supplement registration is required to enter the UK market, the MHRA offers formal borderline classification opinions covering up to 4 products per inquiry, and obtaining this before launch is effectively mandatory for any product touching metabolic or weight management language.[8]
Implications for Nouri: The compliant path across all six markets converges on the same operating constraint: claims must be anchored to substantiated general wellbeing language — "supports healthy weight management" — with no drug-comparison language, no mechanism references (GLP-1 stimulation, metabolism modification), and no implied pharmaceutical equivalence anywhere in the consumer-facing stack, including influencer briefs, UGC, social media captions, and testimonials. The sequencing for multi-market expansion is dictated by lead time: the NPN application for Canada should commence immediately, 12–18 months ahead of any Canadian launch. Australia requires ARTG listing and GMP compliance as the formal pre-market gate. UK and NZ can technically launch faster on a claims-review basis, but the UK's criminal enforcement and AI monitoring posture makes MHRA borderline advice non-negotiable before any weight-management adjacent product goes live. GCC entry gates on halal certification and bilingual labelling as product formulation prerequisites — these cannot be addressed post-formulation without significant reformulation cost.
Dietary supplements in New Zealand are governed by the Dietary Supplements Regulations 1985, administered under the Food Act 2014 by Medsafe (for supplement-specific rules) and the Ministry for Primary Industries (for the broader food framework).[1] Additional compliance touchpoints include the Animal Products Act 1999 (animal-derived ingredients) and the Biosecurity Act 1993.[1][18]
A dietary supplement is legally defined as "substance(s) for oral use that are packed in a controlled dosage form and are intended to supplement the intake of that substance(s) normally derived from food."[1] The controlled dosage form requirement is substantive — bulk powder in an uncontrolled format does not qualify.
Product categorisation turns on three elements simultaneously: ingredients, intended purpose, and manner of presentation in the market — including labelling, advertising, websites, testimonials, and social media.[2][16] No single factor is determinative in isolation.
Under Section 4 of the Medicines Act 1981, a product is considered intended for "therapeutic purpose" if a therapeutic claim is stated or implied in any marketing material, or where active ingredients clearly have a pharmacological action.[16] The four triggers for therapeutic classification:
| Trigger | Regulatory Consequence | Source |
|---|---|---|
| Treatment, diagnosis, or prevention of disease[16] | Classified as medicine — requires Director-General of Health consent | Medicines Act 1981, §4 |
| Modification of a physiological function[16] | Classified as medicine — "increasing metabolism" is explicitly cited as triggering this | Medicines Act 1981, §4; ASA NZ Code |
| Contains a scheduled medicine ingredient[1] | Cannot qualify as dietary supplement regardless of claims | Dietary Supplement Regs 1985 |
| Exceeds maximum daily dose limits[1] | Cannot qualify as dietary supplement | Dietary Supplement Regs 1985, Reg 3 |
| Ingredient | Specific Rule | Source |
|---|---|---|
| Folic acid[1] | Max 300 mcg/daily dose; up to 500 mcg if produced in GMP-certified facility — requires Medsafe verified declaration before supply | Dietary Supplement Regs 1985 |
| Probiotics[1] | Treated as "functional foods" not drugs; health claims require scientific evidence but no independent verification; company-conducted trials accepted | Medsafe guidance |
| Controlled drugs[1] | Cannot be present in any dietary supplement | Misuse of Drugs Act 1975 |
| Multi-ingredient products[2] | Most restrictive classification among all active ingredients applies to whole product | Medsafe categorisation policy |
The terms "complementary health care product" and "natural health product" are widely used in New Zealand commerce but are not currently defined in legislation. No legislation permits marketing of products with low-level therapeutic claims under these labels.[16] Products using these labels still face the full supplement vs. medicine boundary test.
Unlike medicines, dietary supplements undergo no pre-approval process.[1][18] The sponsor (legal distributor) bears full responsibility for safety, quality, and regulatory compliance. This creates a post-market enforcement model where non-compliance is discovered after products reach market.
Government policy on the future of natural health products was agreed 25 September 2024. Cabinet commissioned a Sapere Research Group comparison of NHP regulation across Australia, Canada, EU, UK, USA, and China (published 21 June 2024). Export exemption rules for dietary supplements are also under review.[18] The regulatory landscape for supplements in NZ is therefore in active flux.
Key finding: In New Zealand, the marketing approach alone determines whether a product is classified as a medicine — regardless of actual ingredients. Any claim that "implies, alludes, suggests or refers to a therapeutic purpose" converts a supplement into a medicine subject to full pharmaceutical regulatory requirements.[3]
See also: Strategic Risk (regulatory reclassification as a category threat)
The Therapeutic Goods Administration (TGA) regulates complementary medicines — including vitamins, minerals, nutritional supplements, herbs, and homoeopathic preparations — under the Therapeutic Goods Act 1989.[6][17] Australia does not legally recognise "nutraceutical" as a regulatory category; all products are assessed on intended use and claims.[4]
| Classification | ARTG Label | TGA Pre-Market Review | Claim Level Permitted | Who Self-Certifies |
|---|---|---|---|---|
| Listed Medicine[6][17] | AUST L | No efficacy review | Low-level only (general wellbeing, nutritional support) | Sponsor certifies safety, quality, efficacy |
| Assessed Listed Medicine[4][17] | AUST L(A) | TGA assesses efficacy evidence for indications | Intermediate + low-level claims | Sponsor certifies safety and quality |
| Registered Medicine[4][6] | AUST R | Full safety, quality, and efficacy evaluation | Any level including serious disease claims | Full TGA review required |
Most complementary medicines in the Australian Register of Therapeutic Goods (ARTG) are listed medicines.[6] The listed pathway requires exclusive use of TGA-approved Permissible Ingredients and TGA-approved Permissible Indications.[17]
A product is classified as a therapeutic good if it is presented as having a therapeutic purpose — preventing, treating, curing, alleviating, or managing a disease or condition.[6] The TGA's canonical example: minced garlic in a bottle = likely food; extracted garlic concentrate in a capsule with "relieve cold and flu symptoms" = likely medicine requiring TGA registration.[17] The TGA updated boundary guidance in December 2023, with further examples released June/July 2024.[17]
Key finding: "A change in wording on a label can alter the entire regulatory pathway" — TGA's documented principle for complementary medicines in Australia.[4] Sponsors selecting the AUST L pathway are a single label change away from requiring full pre-market evaluation.
| Update | Date | Key Change |
|---|---|---|
| Permissible Ingredients Determination[6] | 1 March 2024 | New determination commenced; Determination No. 2 (14 June 2024) added 5 new ingredients, revised requirements for 4 |
| Manufacturing Principles Determination 2024[4] | 2024 | New manufacturing standards issued for complementary medicines |
| Probiotic Medicine Quality Guidance[6] | February 2025 | New quality guidance specific to probiotic medicines |
| Post-Market Surveillance Guidance[6] | November 2024 | Updated compliance review guidance for listed medicines |
| International Scientific Guidelines Alignment[6] | 2024 | TGA adopted 19 international scientific guidelines aligning AU technical data requirements with global standards |
TGA standards require: clear active ingredient identification; dosage directions and warning statements; sponsor contact details.[4] Good Manufacturing Practice (GMP) standards are mandatory. Compliance requirements extend to websites, social media, and digital campaigns — not just product packaging.[4]
See also: Competitive Landscape (how competitors navigate the AUST L vs AUST L(A) choice)
The single most operationally significant regulatory principle across all markets Nouri operates in or targets is this: marketing claims determine product classification more than ingredients alone. A supplement making therapeutic claims is reclassified as a medicine in virtually every major jurisdiction.[2][3][4][8][16][17]
| Jurisdiction | Authority | Principle Statement |
|---|---|---|
| New Zealand[3] | Medsafe | "If marketing materials imply, allude, suggest or refer to a therapeutic purpose...then they are medicines" |
| Australia[4] | TGA | "A change in wording on a label can alter the entire regulatory pathway" |
| United Kingdom[8] | MHRA | A product satisfying both food AND medicine conditions will generally be classified as a medicinal product |
| Canada[9] | Health Canada | Licensing based on at least one health claim; claim scope determines regulatory pathway |
| GCC (UAE)[10] | MOHAP / Dubai Municipality | Metabolic or therapeutic claims trigger the MOHAP pathway (higher bar) vs. food supplement route |
Key finding: Nouri's marketing copy is, in every jurisdiction it operates in, a regulatory instrument. The same product with different copy can be either freely sold as a dietary supplement or require prescription-level pharmaceutical approval. Legal review of all consumer-facing language — including social media, influencer briefs, website text, and testimonials — is a first-order compliance requirement, not a secondary check.[3][16][17]
Listed complementary medicines must use only indications drawn from the Therapeutic Goods (Permissible Indications) Determination — the approved claims list.[21] As of 2024, approximately 778 permissible indications are available.[6][21] Each indication contains a therapeutic action and a therapeutic target; no other combinations or paraphrased indications are permitted for listed medicines.[21] Sponsors must certify at ARTG listing that they hold supporting evidence — scientific or traditional — for all claimed indications.[21]
| Claim Category | Example | Status |
|---|---|---|
| Blood pressure reduction[21] | "Lowering blood pressure" | NOT a permitted indication for listed medicines |
| Guaranteed outcomes[11] | "Infallible", "magical", "miraculous", "certain cure" | Prohibited under TGA Advertising Code |
| Universal efficacy[11] | "Effective in all cases" | Prohibited |
| Unprovable claims[11] | Any claim impossible to substantiate | Prohibited |
| Government endorsement[11] | "TGA Approved" | Unlawful (only "TGA Assessed" permitted under specific conditions for assessed/registered medicines) |
| Weight loss synonyms[21] | Substituting other terms for "weight loss" in indications | Controlled — Table 6 of TGA Evidence Guidelines lists prohibited substitutions |
Food Standards Australia New Zealand (FSANZ) administers Standard 1.2.7 (Nutrition, Health and Related Claims) under the Food Standards Australia New Zealand Act 1991.[14] This framework applies to food products and supplemented foods — not to products classified as therapeutic goods under TGA jurisdiction.[14]
| Claim Type | Examples | Pathway | Enforcement |
|---|---|---|---|
| Nutrition Content Claims[14] | "High in fibre", "low fat" | Pre-approved formulas in Standard 1.2.7 | ACCC (AU), NZCC (NZ) |
| General Level Health Claims[14] | 200+ pre-approved food-health relationships; or self-substantiated via systematic review (Schedule 6) + FSANZ notification | Pre-approved list or Schedule 6 self-substantiation | ACCC (AU), NZCC (NZ) |
| High Level Health Claims[14] | Must link to serious disease or biomarker; 13 pre-approved relationships in Schedule 4 only | Schedule 4 only — cannot be self-substantiated | ACCC (AU), NZCC (NZ) |
In New Zealand, dietary supplements regulated under the Dietary Supplements Regulations 1985 and the Supplemented Food Standard (SFS) may incorporate Standard 1.2.7. Permitted ingredients include: vitamins, minerals, botanicals, bioactive substances (herbal extracts, probiotics, glucosamine, soy isoflavones, amino acids, coenzyme Q10, etc.) if safe and suitable.[14]
Regulated by retained Regulation (EC) 1924/2006. All nutrition or health claims must be: (1) authorised under applicable rules; (2) supported by documentary evidence; and (3) listed in the GB or NI health claims register.[8][20] General health-related statements (e.g., "supports immune function") are permitted only if scientifically substantiated, approved by the Nutrition and Health Claims Committee (NHCC), and listed on the official register.[8]
The Nutrition and Health Claims (England) (Amendment) Regulations 2024 — in force 1 October 2024 — enabled local authorities to use improvement notices as light-touch enforcement. Using an unauthorised nutrition or health claim remains a criminal offence.[8]
Natural Health Product licensing in Canada is based on at least one health claim to support at least one medicinal ingredient.[9] Permissible claim types:
Efficacy is far less stringent than prescription drugs — in most cases, reference to Health Canada's publicly available monographs is sufficient.[9] Literature must be submitted supporting both efficacy and safety.
GLP-1 receptor agonists (semaglutide/Ozempic, Wegovy, tirzepatide/Mounjaro) are prescription-only medicines in Australia, New Zealand, the UK, and Canada. Public advertising of these products is prohibited in all four jurisdictions. The prohibition also extends — with documented enforcement — to supplement advertising that implies equivalence to, comparison with, or association with GLP-1 drugs.
Two independent legal grounds prohibit GLP-1 advertising in Australia:[5][15]
Key finding: The TGA's official position: "Advertising prescription-only medicines directly to consumers is prohibited under the Therapeutic Goods Act 1989 as it could create an inappropriate demand for these medicines and lead to unnecessary or harmful prescribing."[5] The medicine shortage impact is documented — illegal promotion of Ozempic has contributed to a global shortage leaving diabetic patients unable to access it.
| Channel / Activity | Status | Source |
|---|---|---|
| Direct-to-consumer advertising[15] | Prohibited | TGA |
| Social media posts (including influencer content)[11] | Prohibited | TGA Advertising Code |
| In-store pharmacy signage[5] | Prohibited (Myers Pharmacy fined $18,780) | TGA enforcement, May 2024 |
| Supplement ads comparing to GLP-1 drugs[15] | Likely prohibited — ASA UK precedent: "medicinal by presentation" | TGA; UK ASA |
| Compounded GLP-1 products (pharmacies)[5][15] | Banned from 1 October 2024 — removed from compounding exemption | TGA; Therapeutic Goods Regulations 1990, Schedule 5, item 6 |
| Wegovy (ARTG registered, not yet available)[5] | Prohibited to advertise | TGA |
| Offender Type | Civil Penalty (per breach) | Source |
|---|---|---|
| Corporations[15] | Up to AU$15,650,000 | TGA (2024–25 figures) |
| Individuals[15] | Up to AU$1,565,000 | TGA (2024–25 figures) |
| Corporations (alternative figure)[5] | Up to $11.1 million | TGA media release |
| Individuals (alternative figure)[5] | Up to $1.11 million + possible jail time | TGA media release |
Note: The two figure sets reflect annual indexation of the Commonwealth civil penalty unit between fiscal years. The lower AU$11.1M / AU$1.11M values correspond to FY2022–23 TGA media release figures; the AU$15.65M / AU$1.565M values correspond to FY2024–25 maxima after penalty-unit indexation (5,000 units for individuals and 50,000 units for corporations, multiplied by the FY2024–25 civil penalty unit value). The FY2024–25 figures are the current operative maxima for breaches occurring in that period.[15]
| Date | Entity | Action | Amount |
|---|---|---|---|
| Jan–Aug 2024[15] | 19 entities | 70+ infringement notices | $1 million total |
| May 2024[5] | Myers Pharmacy Pty Ltd | In-store Ozempic signage | $18,780 |
| 2024[5] | Midnight Health Pty Ltd | 10 infringement notices | $198,000 |
| 2024–25[15] | Multiple online advertisers | TGA requested removal of 3,000+ online ads for weight-loss therapeutic goods | — |
| September 2025[15] | Multiple entities | 10 additional infringement notices | — |
| November 2025[15] | — | TGA issued updated social media advertising guidance | — |
| 2024[5] | Your Solution Compounding Pharmacy | Court-enforceable undertaking | — |
| 2024[12] | Prime Medic Group Pty Ltd + individual | Infringement notices | — |
Per trade press coverage, the UK Advertising Standards Authority issued five rulings in August 2025 against food supplement ads making unlicensed medicinal claims AND unauthorized health claims — all reported as non-compliant.[19]
Per trade press coverage of the ruling, banned claims included: "anti-snack drink", "support metabolism", "reduce blood sugar spikes", "curb cravings." The most egregious banned claims reported were "like GLP-1 drugs just natural" and "boosts GLP-1-production." The reported finding: the supplement implied equivalence to prescription-only medicines (POMs), violating the advertising code.[19]
Per trade press coverage, Facebook ads stated: "Meet MB-1 by Arrae, your all-natural Faux-Zempic!" The ASA was reported as concluding the company "must not state, or imply, that a food supplement was equivalent to or had similar effects to prescription-only medicines used for weight loss, such as Ozempic." The product name "Faux-Zempic" was itself reported as ruled to directly imply drug equivalence.[19]
| Claim Type | Status |
|---|---|
| "Weight Loss Injections", "Weight Loss Pen", "Obesity Treatment Jab"[19] | Prohibited |
| Any reference to "GLP-1" in a supplement context[19] | Prohibited |
| "Stimulates GLP-1", "boosts GLP-1 production"[19] | Prohibited |
| Blood sugar effects / cravings reduction (when framed as drug-equivalent)[19] | Prohibited |
| Metabolism support, appetite control, digestion improvement, glucose reduction (when presented as equivalent to prescription drug mechanism)[19] | Prohibited |
| Unauthorized health claims not on the GB Nutrition and Health Claims Register[19] | Prohibited |
The UK ASA deployed an AI Active Ad Monitoring system in 2025 to proactively scan for GLP-1-adjacent supplement claims — not waiting for consumer complaints.[19] This proactive posture is material for Nouri's marketing operations across all UK-adjacent channels.
In NZ, GLP-1 medications are prescription medicines. Any dietary supplement claim implying metabolic interference — increasing GLP-1 levels, affecting insulin secretion, affecting physiological function through a mechanism associated with GLP-1 — would classify the product as a medicine under the Medicines Act 1981, Section 4.[7] Co-marketing or advertising associating a supplement with a GLP-1 medication requires careful legal review before execution.
| Activity | AU | NZ | UK | Canada |
|---|---|---|---|---|
| Name GLP-1 drugs (Ozempic, Wegovy, Mounjaro) in supplement marketing[5][7][19] | Prohibited | Prohibited | Prohibited | Prohibited |
| Position supplement as "supports GLP-1 treatment"[15][19] | Prohibited | Prohibited | Prohibited | High risk |
| Influencer content referencing prescription weight-loss medicines[11][19] | Prohibited | Prohibited | Prohibited | Prohibited |
| Claim supplement "stimulates GLP-1"[19] | Prohibited | Prohibited | Prohibited | Requires NPN support |
| Co-marketing bundle with GLP-1 drug promotions[15][7] | Significant legal risk | Significant legal risk | Prohibited | High risk |
See also: Strategic Risk (GLP-1 regulatory adjacency as a category-level threat)
The ASA's Therapeutic and Health Advertising Code covers all words and visual depictions in advertising for: therapeutic products (medicines and medical devices), natural health products and dietary supplements, and health services and methods of treatment.[7] Underlying legislation includes the Fair Trading Act 1986, Medicines Act 1981, Medicines Regulations 1984, and Misuse of Drugs Regulations 1977.[7]
The ASA code is explicit: "If an advertiser wishes to claim or imply that a product induces weight loss, that product must have consent to be distributed in New Zealand as a medicine before it can be supplied."[7] Weight management products may be meal replacements or supplements replacing essential vitamins/minerals, but cannot claim weight loss as a stand-alone product — only as associated with a programme including diet and exercise.[7]
| Claim Category | Specific Rule |
|---|---|
| Safety guarantee[7] | Cannot claim product is safe or cannot cause harm |
| Cure claims[7] | Cannot claim product is a "sure cure" |
| Disease treatment (without medicine consent)[7] | Cannot claim treating, preventing, or curing specific diseases |
| Misleading/exaggerated claims[7] | Cannot be misleading, deceptive, or exaggerated |
| Medicine comparisons[7] | Comparisons with medicines or medical devices explicitly prohibited for dietary supplements |
| Therapeutic product names[7] | Product names implying therapeutic purpose prohibited (e.g., "weight loss" in product name) |
| Metabolism claims[7] | "If the product works by increasing metabolism, then the product is legally a medicine because it interferes with the normal operation of a physiological function" |
Testimonials must be consistent with allowable claims, reflect genuine experience, and must not encourage inappropriate or excessive purchase.[7]
The Therapeutic Advertising Pre-vetting System (TAPS) provides a pre-vetting service for advertising. TAPS Consultants are familiar with legislative and guideline requirements.[7][3] However, TAPS guidance does not guarantee compliance or protect from liability — it is a risk management tool, not a safe harbour.
The governing instrument came into full effect 1 July 2022.[11]
"Weight management" is defined to include: weight loss, weight control, weight maintenance, measurement reduction, clothing size reduction, hunger suppression.[11][12]
| Category | Description | Consequence |
|---|---|---|
| Restricted Representations[11] | Claims about serious conditions (cancer, cardiovascular disease, diabetes) | Must obtain prior TGA approval before use |
| Prohibited Representations[11] | Treatment/cure/prevention/diagnosis of serious conditions | Only permitted where necessary for appropriate use or public interest; significant fines apply |
Third-party reviews and comments on social media ARE testimonials and must comply with advertising requirements.[11] Prescription medicines CANNOT be advertised to the public, including via testimonials and social media. UGC (user-generated content) does not provide a safe harbour for brands.
The AANA Code of Ethics applies to advertising in any medium. Key provisions for supplement brands:[12]
The 2024 AANA Code of Ethics Practice Note addresses truthfulness, use of scientific evidence, and social responsibility.[12]
Separately, under the AANA Food & Beverages Advertising Code, advertisements for vitamins and minerals must not claim they are a substitute for good nutrition or a balanced diet.[12]
The Australian Consumer Law prohibits false or misleading representations about goods or services, including health claims. The ACCC applies the ACL alongside (and independently of) the TGA's therapeutic goods advertising framework — meaning non-compliant health claims can trigger enforcement from two regulatory bodies simultaneously.[12]
| Domain | Authority | Instruments |
|---|---|---|
| Food supplements regulation[20] | Food Standards Agency (FSA) | Food Supplements (England) Regulations 2003 (SI 2003/1387); equivalent regulations in Scotland, Wales, Northern Ireland |
| Borderline / medicinal classification[8] | MHRA | Medicines Act 1968; Human Medicines Regulations 2012 |
| Health claims[8][20] | FSA + NHCC | Retained Regulation (EC) 1924/2006; GB/NI Health Claims Register |
| Advertising standards[20] | ASA UK | CAP Code (Section 15); UK Advertising Codes |
Post-Brexit transition under the Nutrition (Amendment etc.) (EU Exit) Regulations 2019 and 2020 transferred responsibilities from EU to UK bodies. Since IP Completion Day (31 December 2020), EU Regulations are incorporated into UK legislation with amendments.[20]
No requirement to register food supplements in the UK.[20] The manufacturer, importer, or retailer bears compliance responsibility. The FSA enforces via post-market controls — parallel to the NZ/AU model of post-market surveillance rather than pre-market approval.
The MHRA's updated borderline guidance determines classification on a case-by-case basis, assessed on:[8]
Tie-break rule: A product satisfying equally well the conditions for both food and medicinal product classification will generally be classified as a medicinal product.[8]
| Claim | Status |
|---|---|
| "Cures arthritis"[8] | Prohibited — medicinal claim on food labelling |
| "Reverses diabetes"[8] | Prohibited — medicinal claim on food labelling |
| Any disease prevention, treatment, or cure claim[8] | Prohibited; triggers mandatory MHRA evaluation and approval |
| GLP-1 equivalence or comparison claims[19] | Prohibited (ASA August 2025 rulings) |
| Unauthorized health claims not on GB Register[8][19] | Criminal offence (Nutrition and Health Claims Regs 2024) |
The Regulations cross-refer to the Annex of retained EU Directive 2002/46/EC: Annex I lists permitted vitamins and minerals; Annex II lists permitted forms of those vitamins and minerals.[20] Non-vitamin/mineral ingredients are not specifically controlled by the Regulations but must be safe and not injurious to health. No national UK legislation sets maximum vitamin/mineral levels in supplements — voluntary guideline safe upper levels come from the 2003 Expert Group on Vitamins and Minerals (EVM) report.[20]
Companies uncertain about classification should complete a Medicines Borderline Advice Form and submit to MHRA before marketing.[8] MHRA provides formal opinions covering up to four products per inquiry. Non-UK companies exporting directly to UK consumers may fall outside MHRA jurisdiction for registration purposes but can still be investigated for advertising breaches.[8]
| Aspect | New Zealand | Australia | United Kingdom |
|---|---|---|---|
| Regulatory body[1][6][20] | Medsafe / MPI | TGA | FSA / MHRA / ASA |
| Pre-market registration[18][6][20] | None | ARTG listing required | None |
| Health claims framework[14][21][8] | FSANZ Standard 1.2.7 (supplemented foods) | TGA ~778 Permissible Indications | Retained EU Reg 1924/2006; GB Health Claims Register |
| GLP-1 supplement comparison claims[7][15][19] | Prohibited | Prohibited | Prohibited (criminal + ASA enforcement) |
| Age restrictions on weight-loss supplements[13] | None | None | 18+ for OTC laxatives; mandatory pharmacist consultation for minors |
| Enforcement posture[13] | Reactive/post-market | Reactive/post-market + active TGA monitoring | Proactive/inter-agency + AI ad monitoring |
Unlike the US dietary supplement model, sale of a natural health product (NHP) in Canada requires a product licence.[9] A Natural Product Number (NPN) is an 8-digit number issued after assessment by Health Canada's Natural and Non-Prescription Health Products Directorate (NNHPD). The NPN must be displayed on the label. Since 2004, approximately 90,000 product licences have been granted.[9]
Semaglutide (Ozempic, Wegovy) is a prescription drug in Canada — not eligible for NPN registration.[9] In 2024, Health Canada approved a generic version of injectable semaglutide (Dr. Reddy's) as the first generic GLP-1 in the G7 nations. Dr. Reddy's filed its application February 2024; Health Canada reviewed within its 180-day target.[9] Generic GLP-1 availability is expected to reduce costs by up to 65% compared to branded versions.[9] Approximately 3 million Canadian adults are currently taking GLP-1 drugs; many more want access but cost is a barrier.[9]
A supplement marketed as a "GLP-1 supplement" with an NPN would contain natural ingredients (e.g., berberine, fibre, plant extracts) that may support metabolic health, but would NOT contain actual GLP-1 pharmaceutical compounds. Any ingredient that is a scheduled drug in Canada must be removed before an NHP formula can proceed to licensing.[9]
Key finding: Canada's NPN system is the most analogous to a formal pre-market approval requirement among Nouri's expansion markets — requiring product licence before sale, unlike NZ, AU (AUST L), and UK which are all self-certification or post-market models. The 90,000 licences granted since 2004 demonstrates pathway viability, but adds meaningful lead time to any Canadian market entry.[9]
The Gulf Cooperation Council (GCC) — Saudi Arabia, UAE, Kuwait, Oman, Qatar, and Bahrain — operates a centralized drug registration system under the GCC Health Council to harmonize pharmaceutical regulations. However, centralized GCC-DR registration is NOT mandatory; manufacturers may pursue national registration, and national registrations in Saudi Arabia and UAE are often quicker and strategically preferred.[10]
The Saudi Food & Drug Authority (SFDA) is considered the most advanced and strict regulatory body in the GCC.[10]
| Requirement | Detail |
|---|---|
| Registration requirement[10] | All food supplement products must be registered with SFDA before entering Saudi market |
| Technical standard[10] | Products must comply with SFDA.FD 55 Food Supplements |
| Logo restriction[10] | Companies NOT allowed to use SFDA logo on product packaging |
| Reference document[10] | Registration Guide of Food Supplements and Energy Drinks |
| 2024 updates[10] | New and updated guidance documents issued Q1 & Q2 2024 |
| Aspect | Detail |
|---|---|
| Key legislation[10] | UAE Federal Law No. 10 of 2015 (health products); Ministerial Decree No. 239 of 2012 (supplement classification) |
| Registration — no medicinal claims[10] | Register through Dubai Municipality Montaji portal |
| Registration — medicinal claims / restricted ingredients[10] | Require classification and registration with MOHAP (higher bar) |
| Halal certification[10] | Mandatory when animal-derived ingredients such as gelatin are present |
| Label language[10] | Bilingual (English + Arabic) required |
| Registration renewal[10] | Typically every 1–3 years depending on licensing authority |
| Technical guidelines[10] | Dubai Municipality DM-HSD-GU29-TGHS2, Version 2 (2024) |
Any metabolic or therapeutic claims trigger the MOHAP pathway (higher regulatory bar). Food supplement claims only are acceptable for the simpler Dubai Municipality Montaji route.[10] All GCC countries follow the CTD (Common Technical Document) format for submissions.[10]
Key finding: Halal certification is a hard entry requirement for any GCC market where Nouri's products contain gelatin capsules or other animal-derived ingredients — not a market-specific nice-to-have. The product formulation must be audited for halal compliance before GCC registration is initiated.[10]
| Classification | Channel | Who Can Sell | Prescription Required |
|---|---|---|---|
| Prescription medicines[18] | Pharmacies only | Registered pharmacist | Yes |
| Restricted medicines[18] | Pharmacies only | Registered pharmacist, no prescription | No |
| Pharmacy-only medicines[18] | Community/hospital pharmacies OR licensed shops | Licensed operator | No |
| General Sale Medicines[18] | Any store | Any retailer | No |
| Dietary supplements[18] | Any channel — pharmacy, grocery, DTC, online, specialty | Any retailer | No |
Dietary supplements face no channel restrictions in New Zealand — provided all therapeutic claims rules are followed.[18]
For listed complementary medicines (AUST L), no specific channel restriction applies — they can typically be purchased from supermarkets, health stores, and pharmacies without seeing a doctor or pharmacist.[6] Prescription-only medicines are pharmacy-only by law.
New Zealand is one of only two countries in the world (alongside the USA) where direct-to-consumer (DTC) advertising of prescription medicines is legal, subject to balanced disclosure requirements.[18] Regulations apply to ALL platforms including internet. Under the Medicines Act and Medicines Regulations 1984, DTC medical advertisements in NZ cannot:
Note: This DTC exception applies to prescription medicines only. Standard no-therapeutic-claims rules still apply to supplements.
Importing dietary supplements for sale in New Zealand requires registration as a Registered Food Importer with MPI (per Regulation 112, Food Act 2014). Business registration under a National Programme or Food Control Plan is required.[18]
| Jurisdiction | Approach | Key Tools | Source |
|---|---|---|---|
| Australia (TGA)[13][15] | Reactive post-market + active monitoring | Infringement notices, court-enforceable undertakings, civil penalties, online ad removal requests, pharmacovigilance program | TGA; PMC 2025 |
| New Zealand (Medsafe)[13] | Reactive/post-market | Compliance reviews, "honour system" adverse event reporting, seizure powers under Medicines Act | PMC 2025; Medsafe |
| United Kingdom (ASA/MHRA)[13][19] | Proactive/collaborative + AI-enabled | ASA rulings (publicly named), AI Active Ad Monitoring, inter-agency coordination, criminal prosecution for unlawful health claims | PMC 2025; NutraIngredients 2025 |
| Saudi Arabia (SFDA)[10] | Pre-market registration gate | Product registration as market entry prerequisite; SFDA.FD 55 compliance audit | ChemLinked |
| Canada (Health Canada)[9] | Pre-market licensing | NPN licence required before sale; approved claims scope enforced post-market | Health Canada |
Detecting and disrupting unlawful supply and advertising of unapproved and high-risk medicines — particularly weight loss medicines — is a stated TGA compliance priority for 2023–25.[15] TGA's post-market oversight includes: a pharmacovigilance program with random and targeted product testing; an "honour system" relying on consumers, sponsors, and health professionals to report adverse events; and publication of Annual Performance Statistics Reports documenting withdrawn or non-compliant products.[13]
Peer-reviewed research (PMC, 2025) examining weight-loss supplement regulation in Australia, USA, and UK concluded:[13]
UK applies the strictest OTC controls to weight-adjacent products among the three markets studied:[13]
| Market | Pre-Market Step Required | Health Claims Framework | GLP-1 Adjacency Risk | Lead Time Estimate |
|---|---|---|---|---|
| New Zealand[1][18] | None (post-market compliance model); MPI food importer registration for imports | FSANZ Standard 1.2.7; no therapeutic claims | High — any GLP-1 mechanism claim reclassifies as medicine | Low — primary constraint is claims review, not registration |
| Australia[6][17] | ARTG listing (AUST L) — sponsor self-certification | ~778 TGA Permissible Indications | High — active TGA enforcement; 70+ infringement notices Jan–Aug 2024 | Moderate — ARTG listing process; GMP compliance |
| United Kingdom[20][8] | None (post-market); MHRA borderline advice recommended pre-launch | Retained EU Reg 1924/2006; GB Health Claims Register | Very High — AI ad monitoring; August 2025 ruling wave; criminal offence for unauthorized claims | Low-Moderate — no registration but claims audit essential; MHRA advice up to 4 products |
| Canada[9] | NPN product licence required before any sale | Structure-function, therapeutic, preventative claims per Health Canada monographs | Moderate — GLP-1 drugs as prescription class established; NHP claims pathway separate | High — NPN licence required; Health Canada review timeline |
| Saudi Arabia[10] | SFDA registration mandatory before market entry | SFDA.FD 55; food supplement claims only (therapeutic claims trigger MOHAP) | Low (GLP-1 context less developed in corpus) | High — SFDA registration; SFDA.FD 55 compliance; 2024 guidance updates |
| UAE[10] | Dubai Municipality Montaji (food supplement claims) or MOHAP (medicinal claims) | Food supplement claims via Montaji; medicinal claims via MOHAP | Low-Moderate (GCC context less developed in corpus) | Moderate — Montaji pathway quicker; halal certification prerequisite; bilingual labelling |
| Action | Applicable Markets | Priority |
|---|---|---|
| Legal audit of all marketing copy for therapeutic claim language[3][16] | All markets | Critical — before any launch |
| Strip or restructure any GLP-1-adjacent claims[15][19] | AU / NZ / UK / Canada | Critical — active enforcement in all four |
| ARTG listed medicine registration (AUST L)[6] | Australia | Required before AU market sale |
| NPN product licence application[9] | Canada | Required before Canadian sale; begin 12–18 months ahead |
| MHRA borderline advice submission[8] | United Kingdom | High — obtain pre-launch clarity on product classification |
| SFDA registration[10] | Saudi Arabia | Required before Saudi market entry |
| Halal certification for gelatin-containing formulations[10] | UAE / Saudi Arabia / GCC | Mandatory if animal-derived excipients used |
| Bilingual labelling (English + Arabic)[10] | UAE / GCC | Mandatory at product entry |
| MPI Registered Food Importer registration[18] | New Zealand (imports) | Required if importing rather than domestic manufacture |
| Establish TAPS pre-vetting relationship (NZ)[7] | New Zealand | Recommended — not a safe harbour but reduces enforcement risk |
Key finding: The NutraIngredients analyst assessment from September 2025 defines the safe operating zone for supplement brands in the GLP-1 era: "The safe zone is narrowing — brands need to focus on general wellbeing claims like 'supports healthy weight management' with substantiation, not drug-comparison language."[19] This is the regulatory floor for Nouri's entire marketing strategy — claims must be anchored to substantiated general wellbeing language, with no mechanisms, no drug references, and no comparative language across all six markets.
See also: Competitive Landscape (how competitors are navigating these same claim boundaries)
See also: Strategic Risk (regulatory reclassification as a category-level threat)